Tositumomab: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
Line 20: | Line 20: | ||
! 167000 | ! 167000 | ||
! 205800 | ! 205800 | ||
! | ! 67000 | ||
|- | |- | ||
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ||
Line 32: | Line 32: | ||
! 68 | ! 68 | ||
! 206 | ! 206 | ||
! | ! 108 | ||
|- | |- | ||
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
Line 38: | Line 38: | ||
! 32939000 | ! 32939000 | ||
! Rituximab | ! Rituximab | ||
! | ! 17000 | ||
|- | |- | ||
! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) | ! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) |